INTRODUCTION {#s1}
============

Serum levels of microRNAs (miRs) of the clusters miR-371-373 and miR-302/367 have been suggested as novel biomarkers of testicular germ cell tumors (GCTs) \[[@R1]--[@R3]\]. Of the candidate miRs, miR-371a-3p appears to be the most promising serum marker of GCT with a sensitivity of 90.1% and specificity of 94.1% \[[@R4], [@R5]\] outperforming the classical markers (alpha fetoprotein, beta human chorionic gonadotropin, lactate dehydrogenase) with their sensitivities of less than 50% \[[@R6]\]. Apparently, miR-371a-3p features almost all of the qualities a valuable tumor marker is supposed to have \[[@R7]\] since it correlates with clinical stages, and tumor sizes, it highlights response (or non-response) to therapy, and it is present in cases with relapsing GCT suggesting a prominent role of this miR upon follow-up examinations \[[@R8]--[@R15]\]. Preliminary data also suggest a possible role of the test upon evaluation of residual masses after chemotherapy \[[@R13], [@R16], [@R17]\].

While lots of clinical data suggest a strong correlation between tumor burden and miR-371a-3p serum expression, only limited evidence is available to show that serum-based miRs do primarily originate from GCT cells and do not represent any unspecific side reaction of the testis to invasive GCT.

Testicular vein blood sampling had demonstrated that the tumor-bearing testis is most likely the source of circulating miR-371a-3p \[[@R18]\].

Early experiments had provided evidence for the presence of miRs 372-373 in GCT tissue \[[@R19]\]. Later, high-throughput screening and microarray expression profiling documented miRs 371-373 to be present in tissue of GCTs \[[@R20]--[@R24]\]. A study using RNA extraction from formalin-fixed paraffin embedded GCT tissue again demonstrated the presence of miR-371a-3p in tumor tissue with different expression levels in the various histological subtypes of GCT \[[@R25]\]. All of these studies did not directly compare the miR-expression levels in tumor tissue with corresponding serum levels in the individual patients. The only study to date that evaluated both tissue expression levels and corresponding serum levels did not find a clear correlation between these levels \[[@R26]\].

The aim of the present study was to further clarify the origin of circulating miR-371a-3p by measuring this miR in serum of patients with GCT and concurrently in tissues of the tumor and of the contralateral testes in the same patients. The second goal was to explore if increasing levels of miR371 in GCT tissue would translate into higher serum levels of the miR.

RESULTS {#s2}
=======

Results of microRNA expression investigations in tissues {#s2_1}
--------------------------------------------------------

The median miR-371a-3p expressions in tumor, corresponding contralateral testicular tissue, testicular tissue of healthy controls, and non-testicular tissue of testis-surrounding tunica vaginalis were RQ = 7,040,480.1 (IQR 4,713,672.2--13,518,390.0), RQ = 40,974.1 (IQR 30,119.7--50,549.9), RQ = 37,081.7 (IQR 31,617.2--53,543.4), and RQ = 1,204.9 (IQR = 237.5--7,809.9) respectively. Thus, the individual miR-371a-3p levels found in tumor tissue are on average 399-fold higher than those of the corresponding contralateral testicular tissue (*p* \< 0.001) ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Likewise, expression levels are significantly higher in GCT tissue than in healthy testicular tissue (*p* \< 0.001). MiR-371a-3p expression in healthy testicular tissue is not significantly different from that in contralateral testicular tissue (*p =* 0.985). The miR-371a-3p expression in non-testicular tissue (tunica vaginalis) showed 30.8-times lower values than testicular tissue of healthy controls (*p* \< 0.05) ([Figure 2](#F2){ref-type="fig"}). In addition, one sample of epididymis was analyzed with the lowest miR-371a-3p expression of all tissue samples (RQ = 42.03) ([Table 1](#T1){ref-type="table"}). There is no difference detectable between the miR-371a-3p expression of seminomas and nonseminomas (*p =* 0.941). Likewise, there is no difference between miR-371a-3p expressions in tissues of CS1 and CS 2/3 cases (*p =* 0.262) ([Supplementary Figures 1](#SD1){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}).

![Individual results of measuring miR-371a-3p expressions in GCT tumor tissue samples (dark grey) and the corresponding contralateral testicle (light grey).\
*n* = 38. The patient ID is identical with data sets in [Table 1](#T1){ref-type="table"}. The y-axis is displayed in a logarithmic scale.](oncotarget-11-1462-g001){#F1}

![Relative miR-371a-3p expression in GCT tissue (*n* = 38) and corresponding contralateral testicular tissue (*n* = 38) of the same patients, healthy controls (*n* = 5) and non-testicular tissue samples of the tunica vaginalis (*n* = 4).\
The y-axis is plotted in a logarithmic scale. ^\*\*\*^ *p* \< 0.001.](oncotarget-11-1462-g002){#F2}

###### Clinical data of analyzed patients

  Patient ID   Age \[yrs\]     Diameter \[mm\]   Histology      Clinical Stage   site                   RQ miR-371a-3p
  ------------ --------------- ----------------- -------------- ---------------- ---------------------- ----------------
  1            38              46                Seminoma       CS2              Contralateral tissue   30,119.70
  GCT tissue   13,518,389.95                                                                            
  Serum        2,881.17                                                                                 
  2            34              36                Seminoma       CS1              Contralateral tissue   226,385.18
  GCT tissue   15,854,840.19                                                                            
  Serum        5,509.17                                                                                 
  3            38              19                Seminoma       CS1              Contralateral tissue   6,555.18
  GCT tissue   4,490,423.24                                                                             
  Serum        669.09                                                                                   
  4            28              31                Non-Seminoma   CS2              Contralateral tissue   40,019.62
  GCT tissue   3,547,619.87                                                                             
  Serum        6,537.03                                                                                 
  5            29              24                Non-Seminoma   CS1              Contralateral tissue   27,715.78
  GCT tissue   4,713,672.19                                                                             
  Serum        3,287.19                                                                                 
  6            36              54                Seminoma       CS1              Contralateral tissue   43,490.72
  GCT tissue   19,655,367.47                                                                            
  Serum        39,571.18                                                                                
  7            32              42                Seminoma       CS1              Contralateral tissue   39,196.03
  GCT tissue   22,113,437.94                                                                            
  Serum        41,500.32                                                                                
  8            51              18                Seminoma       CS1              Contralateral tissue   44,404.55
  GCT tissue   3,088,382.47                                                                             
  Serum        1,096.01                                                                                 
  9            45              67                Seminoma       CS1              Contralateral tissue   31,181.87
  GCT tissue   3,109,863.87                                                                             
  Serum        7,068.64                                                                                 
  10           41              45                Seminoma       CS1              Contralateral tissue   28,494.98
  GCT tissue   3,109,863.87                                                                             
  Serum        6,313.85                                                                                 
  11           25              26                Seminoma       CS1              Contralateral tissue   2,245,211.62
  GCT tissue   6,439,065.97                                                                             
  12           36              31                Seminoma       CS1              Contralateral tissue   49,612.64
  GCT tissue   1,544,191.24                                                                             
  Serum        2,131.85                                                                                 
  13           40              37                Seminoma       CS1              Contralateral tissue   47,922.65
  GCT tissue   1,749,389.37                                                                             
  Serum        10,019.87                                                                                
  14           27              41                Non-Seminoma   CS1              Contralateral tissue   66,839.81
  GCT tissue   19,929,746.17                                                                            
  Serum        120,356.55                                                                               
  15           36              33                Non-Seminoma   CS1              Contralateral tissue   28,693.18
  GCT tissue   18,466,664.88                                                                            
  Serum        4,629.83                                                                                 
  16           37              52                Non-Seminoma   CS1              Contralateral tissue   26,586.75
  GCT tissue   6,620,092.75                                                                             
  Serum        40,760.69                                                                                
  17           30              22                Seminoma       CS2              Contralateral tissue   43,793.22
  GCT tissue   26,480,371.01                                                                            
  Serum        2,652.53                                                                                 
  18           34              73                Seminoma       CS3              Contralateral tissue   46,290.23
  GCT tissue   10,103,977.53                                                                            
  Serum        56,414.42                                                                                
  19           31              68                Seminoma       CS1              Contralateral tissue   44,036.74
  GCT tissue   8,110,840.54                                                                             
  Serum        4,772.14                                                                                 
  20           49              18                Seminoma       CS1              Contralateral tissue   62,623.65
  GCT tissue   9,930,397.24                                                                             
  Serum        288.5                                                                                    
  21           47              30                Seminoma       CS1              Contralateral tissue   46,002.35
  GCT tissue   841,392.83                                                                               
  Serum        100.78                                                                                   
  22           34              34                Seminoma       CS1              Contralateral tissue   85,902.95
  GCT tissue   34,412,276.52                                                                            
  Serum        16,913.42                                                                                
  23           34              33                Seminoma       CS1              Contralateral tissue   34,646.45
  GCT tissue   5,083,603.22                                                                             
  Serum        469.32                                                                                   
  24           38              50                Non-Seminoma   CS3              Contralateral tissue   1,167,847.12
  GCT tissue   7,899,993.31                                                                             
  Serum        4,434.08                                                                                 
  25           34              11                Seminoma       CS1              Contralateral tissue   37,210.44
  GCT tissue   5,859,800.02                                                                             
  Serum        290.67                                                                                   
  26           35              75                Seminoma       CS2              Contralateral tissue   50,549.88
  GCT tissue   10,076,002.16                                                                            
  Serum        3,402.60                                                                                 
  27           31              n\. a.            Non-Seminoma   CS2              Contralateral tissue   25,931.54
  GCT tissue   6,601,763.38                                                                             
  Serum        32,461                                                                                   
  28           41              6                 Seminoma       CS1              Contralateral tissue   32,214.44
  GCT tissue   2,191,397.85                                                                             
  Serum        445.85                                                                                   
  29           66              29                Seminoma       CS2              Contralateral tissue   51,647.83
  GCT tissue   6,891,659.54                                                                             
  Serum        2,007.83                                                                                 
  30           53              42                Seminoma       CS1              Contralateral tissue   40,860.52
  GCT tissue   7,189,300.62                                                                             
  31           47              37                Seminoma       CS2              Contralateral tissue   40,550.16
  GCT tissue   8,585,198.14                                                                             
  Serum        231.91                                                                                   
  32           52              48                Seminoma       CS1              Contralateral tissue   166,068.62
  GCT tissue   6,777,961.45                                                                             
  Serum        840.1                                                                                    
  33           40              56                Seminoma       CS1              Contralateral tissue   53,692.02
  GCT tissue   13,792,876.25                                                                            
  Serum        4,638.43                                                                                 
  34           30              45                Non-Seminoma   CS2              Contralateral tissue   41,087.73
  GCT tissue   5,743,186.58                                                                             
  Serum        11,405.33                                                                                
  35           47              14                Non-Seminoma   CS1              Contralateral tissue   32,709.45
  GCT tissue   13,499,662.47                                                                            
  Serum        516.07                                                                                   
  36           34              47                Seminoma       CS1              Contralateral tissue   25,468.39
  GCT tissue   5,799,190.10                                                                             
  Serum        9,597.35                                                                                 
  37           51              22                Seminoma       CS1              Contralateral tissue   28,593.90
  GCT tissue   10,547,662.66                                                                            
  Serum        3,634.19                                                                                 
  38           47              16                Seminoma       CS2              Contralateral tissue   4,060.44
  GCT tissue   27,376,221.46                                                                            
  Serum        18,247.61                                                                                
  39           47              0                 Control        normal           Control                31,617.16
  40           63              0                 Control        normal           Control                53,543.36
  41           19              0                 Control        normal           Control                37,081.71
  42           60              0                 Control        normal           Control                28,298.15
  43           54              0                 Control        normal           Control                81,156.55
  44           78              0                 Control        normal           *Tunica vaginalis*     138.88
  45           20              0                 Control        normal           *Tunica vaginalis*     336.12
  46           52              0                 Control        normal           *Tunica vaginalis*     42.03
  47           33              0                 Control        normal           *Tunica vaginalis*     13,546.11
  48           46              0                 Control        normal           Epididymis             2,073.66

Abbreviations: CS: Clinical stage, GCT: Germ cell tumor, mm: millimeter, RQ: Relative quantity, yrs: Years.

The ROC analysis based on miR measurements of GCT tissue and the corresponding contralateral tissue in 38 patients revealed an area under the curve of 0.997. GCT tissue can thus be discriminated from the corresponding contralateral tissue with a diagnostic sensitivity of 100% and a specificity of 94.7% ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

Comparison of miR-371a-3p expression in tissue with serum levels {#s2_2}
----------------------------------------------------------------

MiR-371a-3p expression levels in GCT tissue are significantly higher than corresponding serum levels (*p* \< 0.001) ([Figure 3](#F3){ref-type="fig"}). There is a significant positive correlation between tissue levels and those found in serum (*p* \< 0.05) (r^2^ = 0.181) ([Figure 4A](#F4){ref-type="fig"}). The correlation is stronger in the sub cohort of CS1 patients (*p* \< 0.05) (r^2^ = 0.257) ([Figure 4B](#F4){ref-type="fig"}) than in cases with CS2 and CS3 where it is not significant (*p* \> 0.05) (r^2^ = 9.5 × 10^--5^) ([Figure 4C](#F4){ref-type="fig"}).

![Relative miR-371a-3p expression in GCT tissue (*n* = 38) and corresponding preoperative serum samples of the same patients (*n* = 36).\
The y-axis is plotted in a logarithmic scale. ^\*\*\*^ *p* \< 0.001.](oncotarget-11-1462-g003){#F3}

![Scatterplot of the relative miR-371a-3p expression in GCT tissue and corresponding serum levels.\
The axes in all parts are depicted in a logarithmic scale. (**A**) Entire GCT cohort (*n* = 36) (*p* ≤ 0.05) (r^2^ = 0.181). (**B**) Only CS1 patients (*n* = 25; *p* ≤ 0.05) (r^2^ = 0.257). (**C**) Only CS2/3 patients (*n* = 11; *p* ≥ 0.05) (r^2^ = 9.5 × 10^−5^).](oncotarget-11-1462-g004){#F4}

Results of *in situ* hybridization {#s2_3}
----------------------------------

[Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"} show the ISH results in the various GCT subtypes. The blue stain highlights cells expressing miR-371a-3p intracellularly ([Figures 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). An expression of miR-371a-3p was found in all subtypes of GCT except teratoma ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). Identification of the different subtypes was achieved by additional staining with OCT4 for EC ([Figure 5C](#F5){ref-type="fig"}), PLAP for seminoma ([Figure 6C](#F6){ref-type="fig"}) and Glypican 3 for YST ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). In contralateral tissue only isolated germ cells showed blue ISH signals.

![Detection of miR-371a-3p in GCT tumor (EC) via *in situ* hybridization.\
(**A**) *In situ* hybridization with a probe against miR-371a-3p causes blue staining in cells. (**B**) Section from A. (**C**) Immunohistochemical staining of the same area with an OCT4 antibody for identification of EC cells. (**D**) H&E staining of the same area.](oncotarget-11-1462-g005){#F5}

![Detection of miR-371a-3p in GCT mixed tumor including SE and YST via *in situ* hybridization.\
(**A**) *In situ* hybridization with a probe against miR-371a-3p causes blue staining in cells. (**B**) Section from A. (**C**) Immunohistochemical staining of the same area with PLAP antibody for identification of SE cells. (**D**) H&E staining of the same area.](oncotarget-11-1462-g006){#F6}

DISCUSSION {#s3}
==========

There are five main results of this study: (1) The miR-371a-3p expression levels are markedly higher in GCT tissue than in the tissue of the contralateral testis and in normal testes, while non-testicular tissue from testis-surrounding layers (tunica vaginalis) has even much lower expression. (2) There is clear evidence from ISH studies that miR-371a-3p is localized within GCT tumor cells. (3) The miR expression level in GCT tissue is much higher than in serum. (4) In patients with localized disease (CS1), the GCT tissue miR-levels significantly correlate with the corresponding serum levels. (5) There is a baseline miR-371a-3p expression in tissues of contralateral testes of GCT patients and also in normal testes.

MiR-371a-3p levels in the tissues of tumor and contralateral testis {#s3_1}
-------------------------------------------------------------------

A pair-wise comparison of the expression of miR-371a-3p in GCT tissue with corresponding contralateral testicular tissue is a unique opportunity to look for the cellular origin of circulating miR-371a-3p molecules. The miR-level in GCT tissue is 399-fold higher than in contralateral testis tissue and the difference between GCT tissue and testicular tissue of control patients is almost the same. This result clearly points to the GCT tissue as the source of circulating miR-371a-3p. Previous reports had already pointed to the presence of the miR-371-373 cluster in GCT tissue, without quantitative measurements \[[@R20]\], \[[@R21]\]. Our result is consistent with data from measuring the miR in testicular vein blood where a 195-fold higher level was found than in systemic circulation \[[@R18]\]. The present finding of a base-line expression of miR-371a-3p in contralateral testis tissue and in healthy testicular tissue mirrors the finding of a 4-fold higher miR-expression in testicular vein blood compared to peripheral blood in healthy males \[[@R18]\]. These data suggest the presence of this particular miR even in normal testicular tissue though in low quantity and not exclusively in GCT tissue. This assumption is supported by the findings of Boellaard *et al.* who recently documented the presence of miR-371a-3p in normal testicular tissue and its absence in other parts of the urogenital tract \[[@R27]\]. As miR-371 has been shown to be specifically associated with human stem cells \[[@R28]--[@R30]\] and as it is found in seminal plasma, too \[[@R31], [@R32]\], it is rational to assume that this miR is specifically generated by normal testicular germ cells and most probably even more by the cells of GCT.

In serum, patients with nonseminomas showed significantly higher miR-371a-3p expression, and CS2/3 patients had higher levels than those with CS1 \[[@R5]\]. In tissue no difference was detectable between the miR-371a-3p expression of seminomas and nonseminomas nor between tissues of CS1 and CS 2/3 cases. Yet, these results should be interpreted with caution as only a small patient collective was examined.

Intracellular localization of miR-371a-3p by ISH {#s3_2}
------------------------------------------------

*In situ* hybridization clearly demonstrated microRNA-371-3p to be localized intracellularly in the cells of GCT. Thus, the ISH experiments morphologically supplement the data obtained by measuring the miR in homogenized GCT tissue.

In conjunction with previous reports on the presence of the miR-371-373 cluster in GCT tissue \[[@R20], [@R21], [@R25], [@R33]\] there is now ample evidence for the origin of circulating miR-371a-3p from testicular tumor cells.

Of note, all subtypes of GCT except teratoma stained positive for the miR-371a-3p probe. The absence of miR-371a-p staining in teratoma cells is consistent with the non-expression of this miR in serum of GCT patients \[[@R4], [@R5], [@R16]\]. Likewise, in an evaluation of miR-371a-3p expression levels in GCT subtypes by RNA extraction from formalin fixed paraffin embedded orchiectomy specimens, Vilela-Salgueiro *et al.* revealed a strong expression in all GCT subtypes except teratoma \[[@R25]\]. The reason for the non-expression of the miR by teratoma is probably related to the analogies of GCT biology and the human embryonal development \[[@R34], [@R35]\]. While most of the GCT subtypes mimic early developmental stages of embryonal development and accordingly retain their biochemical characteristics including the microRNA profile of stem cells, the teratoma subtype represents a more advanced and more mature histological subtype that has lost all of the biochemical characteristics of stem cells particularly the typical expression of miR-371a-3p \[[@R36]\].

Correlation of miR-expression levels in tissue with serum levels {#s3_3}
----------------------------------------------------------------

Systematic paired measurements of miR-expression levels in GCT tissue and corresponding serum levels had not been reported so far. One early pilot study had indicated that miR-expression levels of tissue and serum do not correlate \[[@R24]\]. However, the present systematic analysis of 36 patients revealed a significant correlation of the expression levels of the two compartments. It is of note that this correlation was not significant in cases with clinical stages CS2 and 3. As in advanced clinical stages the marker substance is released from both the primary tumor and metastatic seeds it is rational that the correlation of tissue expression with serum levels is only significant in cases confined to the testis. The serum level of circulating miR-371a-3p is obviously a product of the number of miR-producing tumor cells (tumor bulk) as shown previously \[[@R5]\] and of the specific secreting capacity of the individual GCT as shown herein. Most probably, additional biological determinants e. g. direct vascular invasion of the tumor and other hitherto unknown factors do also affect the serum level of miR-371a-3p.

In all, the present evaluation confirms the understanding that circulating miR-371a-3p-are specifically derived from cells of testicular germ cell neoplasms.

This miR, thus represents a specific tumor marker for GCTs, which is not expressed in other diseases. By contrast, the specificity of the classical tumor marker AFP is considerably hampered by its association with non-GCT related conditions, such as liver diseases \[[@R37]\].

MATERIALS AND METHODS {#s4}
=====================

Patients for tissue and serum investigations {#s4_1}
--------------------------------------------

Preoperative serum samples and corresponding tissue specimens were collected from patients (median age 36.5) undergoing surgery for testicular tumor. GCT tissue was taken from 38 orchiectomy specimens, and contralateral testis tissue was taken from corresponding contralateral biopsy specimens. This surgical procedure was routinely performed on all patients with suspected testis tumor to look for Germ cell neoplasia *in situ* (GCNis) according to institutional guide-lines. None of the patients enrolled in this study had contralateral GCNis. All tissue specimens were kept frozen at --80° C under further processing. Histologically, the GCT tissue specimens consisted of 29 seminomas and nine nonseminomas. Clinically, 27 patients had clinical stage 1 (CS1) and eleven CS 2 and 3 (CS2/3). Preoperative serum samples were obtained from 36 of the 38 patients. For control, testicular tissue was obtained from five men without GCT undergoing orchiectomy for epididymitis. Furthermore, four samples of testis surrounding tunica vaginalis and one specimen of the epididymis were analyzed. All patients had given informed consent prior to surgery. Ethical approval of the study was provided by Ärztekammer Bremen (reference No 301, 2011). All study activities had been conducted according to the Declaration of Helsinki of the World Medical Association (as amended by the 64th General Assembly, 2013). Individual data of the patients and controls are listed in [Table 1](#T1){ref-type="table"}.

Patients for histological investigation of presence of microRNAs in GCT cells {#s4_2}
-----------------------------------------------------------------------------

Formalin-fixed paraffin-embedded (FFPE) samples of six patients with testicular GCTs were analyzed by immunohistochemistry and *in situ* hybridization (ISH) to look for the presence of miR-371a-3p in tumor tissue. Histologically, the GCTs comprised of three mixed nonseminomatous tumors (embryonal carcinoma, yolk sac tumor, and chorio carcinoma), one pure seminoma, one pure embryonal carcinoma and one teratoma. In addition, one tissue specimen of a contralateral testis was analyzed.

Extraction and measurement of miRNAs {#s4_3}
------------------------------------

Tumor and contralateral testis tissue (10--50 mg) was homogenized in 1000 μL TRIzol^®^ Reagent following the manufacturer's instructions (Fisher Scientific, Schwerte, Germany) using a TissueLyser (Qiagen, Hilden, Germany) with 5 mm steel beads for 10 min at 30 Hz. The extracted RNA was resuspended in 50 μl nuclease-free water.

For the measurement of miR-371a-3p levels, RNA was isolated from 200 μL Serum using the miRNeasy mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's description. Reverse transcription (RT) was performed with 10--20 ng/μL RNA isolated from tissue and 6 μL RNA isolated from Serum, using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). Standard PCR was carried out for preamplification of the cDNA with TaqMan Assays for miR-371a-3p (assay ID 002124) and the endogenous control miR-93-5p (assay ID 000432) in a 1:100 dilution. Measurement of the miRNA expression was performed with quantitative real-time PCR (RT-qPCR) on a 7500 Fast Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) using FAST Start Universal Probe Master (Roche Diagnostics, Mannheim, Germany) and the undiluted TaqMan Assays. The relative quantity (RQ) was calculated using the 2^-ΔΔCT^-method \[[@R38]\].

Immunohistochemistry {#s4_4}
--------------------

For morphological identification of the histological type of GCTs sections of 5 μm of FFPE-blocks were analyzed with hematoxylin and eosin stain (H&E stain), OCT4, PLAP and glypican 3. Staining with hematoxylin and eosin with standard histological techniques were used to distinguish between tumor-free areas and tumor tissue. OCT4 staining for identification of embryonal carcinomas (EC), PLAP staining for seminomas (SE) and glypican 3 for yolk-sac tumors (YST) (Diagnostic BioSystems, Pleasanton, CA, USA) were then conducted according to institutional standard operating procedures \[[@R39], [@R40]\].

MicroRNA *in situ* hybridization {#s4_5}
--------------------------------

After immunohistochemical identification of the particular GCT-subtypes, the corresponding tumor sections were subsequently processed for *in situ* hybridization (ISH) with a miRCURY LNA probe (Exiqon, Vedbaek, Denmark; probe ID 38555-15) specific for miR-371a-3p. The protocol was performed according to the manufacturer's instructions using a proteinase-K concentration of 15 μg/ml, a hybridization temperature of 51° C and a probe concentration of 80 nM. Microscopic evaluations were performed on an Axioskop 2 plus microscope (Zeiss, Göttingen, Germany). Histological findings were documented using the AxioCam HRc digital camera (Zeiss, Göttingen, Germany) and then edited with AxioVision Software v.4.8 (Zeiss, Göttingen, Germany). Presence of miR-371a-3p within GCTs was defined by distinct blue staining of the cells, and accordingly, only these cells were considered miR-371a-3p positive. Only the presence or absence of the miR-371a-3p in the specimen was evaluated, no quantification was attempted.

Statistical methods {#s4_6}
-------------------

The Wilcoxon signed rank test was used for comparison of dependent subgroups. The Mann-Whitney U test was used to compare median miRNA expressions among the various subgroups. Receiver Operating characteristics (ROC) curves were calculated to analyze the sensitivity and specificity of tissue miR-levels to distinguish GCT tissue from non-tumorous tissue. Spearman's rank correlation coefficient was calculated to determine correlations. All tests were two-sided and significance was assumed at *p* \< 0.05. Statistical analysis was performed using SPSS version 24 (IBM, Armonk, NY, USA).

LIMITATIONS {#s5}
===========

The results of the present study rest on 36 patients only, thus the statistical power is still limited. With respect to sample processing, the time for transfer of the tissue specimens from operation site to the laboratory i. e. the time-interval until conservation in the freezer (--80° C) varied from 12 hours to 36 hours depending on the conditions of surface mail. Thus, deterioration of some samples during transfer cannot entirely be excluded. We could not correlate the miR-measurements in contralateral testicular tissue specimens with the quality of spermatogenesis because these data were not available.

CONCLUSIONS {#s6}
===========

The present study provides much of evidence for the understanding that circulating miR-371a-3p molecules are specifically derived from testicular GCT cells. The inability of teratoma cells to produce miR-371a-3p is confirmed on the tissue level. There is a significant correlation of the miR-expression levels in GCT tissue with corresponding serum levels. Normal testicular tissue displays a low baseline expression of miR-371a-3p pointing to the role of the miR in human stem cells.
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:   Lactate dehydrogenase

miR

:   micro RNA

M371

:   miR-371a-3p

OCT4

:   Octamer-binding transcription factor 4

PLAP

:   Placental alkaline phosphatase

qPCR

:   Quantitative real-time PCR

RT

:   Reverse transcription

ROC

:   Receiver operating characteristics

RQ

:   Relative quantity

SE

:   Seminoma

SPSS

:   Statistical package for the social sciences

YST

:   Yolk-sac tumor
